Luminita Pricop

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Iain B. McInnes, Philip J. Mease, Bruce Kirkham et al. · The Lancet · 2015 · 850 citations

Life Sciences, Immunology, Pharmacotherapy +15

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

Philip J. Mease, Iain B. McInnes, Bruce Kirkham et al. · New England Journal of Medicine · 2015 · 740 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

Philip J. Mease, Désirée van der Heijde, Robert Landewé et al. · Annals of the Rheumatic Diseases · 2018 · 301 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

Iain B. McInnes, Frank Behrens, Philip J. Mease et al. · The Lancet · 2020 · 282 citations · Full text

Medicine, Clinical Sciences, Immunology +12

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

Karel Pavelka, Alan Kivitz, Eva Dokoupilová et al. · Arthritis Research & Therapy · 2017 · 233 citations · Full text

Medicine, Immunology, Pharmacotherapy +17